



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

December 7, 2022

Thomas Schuetz  
Chief Executive Officer  
Compass Therapeutics, Inc.  
80 Guest Street  
Suite 601  
Boston, Massachusetts 02135

**Re: Compass Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**Filed December 2, 2022**  
**File No. 333-268652**

Dear Thomas Schuetz:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Dillon Hagius at 202-551-7967 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: James Xu